# Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19

> **NCT04479358** · PHASE2 · TERMINATED · sponsor: **University of Chicago** · enrollment: 85 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Tocilizumab
- **DRUG:** Tocilizumab
- **OTHER:** Standard of Care
- **OTHER:** Standard of Care

## Key facts

- **NCT ID:** NCT04479358
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-10
- **Primary completion:** 2024-03-01
- **Final completion:** 2025-02-10
- **Target enrollment:** 85 (ACTUAL)
- **Why stopped:** Lack of recruitment of patients into the trial
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04479358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04479358, "Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04479358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*